Taigen Biopharmaceuticals Holdings Ltd (4157) - Total Assets

Latest as of December 2025: NT$1.17 Billion TWD ≈ $36.77 Million USD

Based on the latest financial reports, Taigen Biopharmaceuticals Holdings Ltd (4157) holds total assets worth NT$1.17 Billion TWD (≈ $36.77 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Taigen Biopharmaceuticals Holdings Ltd (4157) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Taigen Biopharmaceuticals Holdings Ltd - Total Assets Trend (2010–2025)

This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Taigen Biopharmaceuticals Holdings Ltd to see how much of total assets are deployed in long-term investments.

Taigen Biopharmaceuticals Holdings Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Taigen Biopharmaceuticals Holdings Ltd's total assets of NT$1.17 Billion consist of 96.0% current assets and 4.1% non-current assets.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	12.4%
Accounts Receivable	NT$5.01 Million	0.4%
Inventory	NT$76.10 Million	6.5%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$0.00	0.0%
Goodwill	NT$0.00	0.0%

Asset Composition Trend (2010–2025)

This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Taigen Biopharmaceuticals Holdings Ltd (4157) total market value.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Taigen Biopharmaceuticals Holdings Ltd's current assets represent 96.0% of total assets in 2025, an increase from 82.9% in 2010.
Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, down from 77.9% in 2010.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2010.
Asset Diversification: The largest asset category is inventory at 6.5% of total assets.

Taigen Biopharmaceuticals Holdings Ltd Competitors by Total Assets

Key competitors of Taigen Biopharmaceuticals Holdings Ltd based on total assets are shown below.

Company	Country	Total Assets
Tubize-Fin BR:TUB	Belgium	€1.93 Billion
Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHG:603392	China	CN¥13.76 Billion
Amicus Therapeutics Inc NASDAQ:FOLD	USA	$949.87 Million
China Resources Boya Bio pharmaceutical Group Co Ltd SHE:300294	China	CN¥8.41 Billion
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	China	CN¥772.57 Million
Jiangsu Sihuan Bioengineering Co Ltd SHE:000518	China	CN¥509.14 Million
Yantai Zhenghai Bio-Tech Co Ltd SHE:300653	China	CN¥964.85 Million
Jiangsu GDK Biotechnology Co Ltd SHG:688670	China	CN¥1.48 Billion

Taigen Biopharmaceuticals Holdings Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	13.48	23.57	8.90
Quick Ratio	12.56	22.64	8.35
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$1.04 Billion	NT$1.04 Billion	NT$283.97 Million

Taigen Biopharmaceuticals Holdings Ltd - Advanced Valuation Insights

This section examines the relationship between Taigen Biopharmaceuticals Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	5.88
Latest Market Cap to Assets Ratio	0.16
Asset Growth Rate (YoY)	-0.6%
Total Assets	NT$1.17 Billion
Market Capitalization	$192.20 Million USD

Valuation Analysis

Below Book Valuation: The market values Taigen Biopharmaceuticals Holdings Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Taigen Biopharmaceuticals Holdings Ltd's assets decreased by 0.6% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Taigen Biopharmaceuticals Holdings Ltd (2010–2025)

The table below shows the annual total assets of Taigen Biopharmaceuticals Holdings Ltd from 2010 to 2025.

Year	Total Assets	Change
2025-12-31	NT$1.17 Billion ≈ $36.77 Million	-0.60%
2024-12-31	NT$1.17 Billion ≈ $37.00 Million	-4.52%
2023-12-31	NT$1.23 Billion ≈ $38.75 Million	+17.46%
2022-12-31	NT$1.05 Billion ≈ $32.99 Million	-24.83%
2021-12-31	NT$1.39 Billion ≈ $43.88 Million	+150.30%
2020-12-31	NT$556.45 Million ≈ $17.53 Million	-41.19%
2019-12-31	NT$946.11 Million ≈ $29.81 Million	-20.34%
2018-12-31	NT$1.19 Billion ≈ $37.42 Million	-21.97%
2017-12-31	NT$1.52 Billion ≈ $47.96 Million	+84.85%
2016-12-31	NT$823.45 Million ≈ $25.94 Million	+31.65%
2015-12-31	NT$625.46 Million ≈ $19.71 Million	-43.05%
2014-12-31	NT$1.10 Billion ≈ $34.60 Million	+125.74%
2013-12-31	NT$486.49 Million ≈ $15.33 Million	-33.72%
2012-12-31	NT$733.95 Million ≈ $23.12 Million	+20.22%
2011-12-31	NT$610.52 Million ≈ $19.23 Million	-45.15%
2010-12-31	NT$1.11 Billion ≈ $35.06 Million	--

About Taigen Biopharmaceuticals Holdings Ltd

TWO:4157 Taiwan Biotechnology

Market Cap

$192.20 Million

NT$6.10 Billion TWD

Market Cap Rank

#16764 Global

#846 in Taiwan

Share Price

NT$8.57

Change (1 day)

-1.95%

52-Week Range

NT$7.52 - NT$15.60

All Time High

NT$37.39